# Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia

- Link: https://www.thailand-business-news.com/pr-news/informa-markets-puts-bangkok-at-the-center-of-southeast-asias-pharma-industry-uniting-400-exhibitors-experts-from-70-countries-at-cphi-south-east-asia
- Published: 2026-05-24T12:00:00+07:00
- Author: PR Newswire

_The Region’s Premier Pharma Exhibition Returns to Bangkok, __Elevating Thailand’s
Role in the ASEAN Pharmaceutical Supply Chain_

BANGKOK, May 24, 2026 /PRNewswire/ — Informa Markets sets to organise CPHI South
East Asia from 8–10 July 2026 at Queen Sirikit National Convention Center under 
the theme _"The Gateway to the ASEAN Pharma Industry."_ The event is a comprehensive
pharmaceutical manufacturing exhibition, technology showcase, and conference for
Southeast Asia, featuring innovations from more than 400 companies worldwide.

Highlights include international pavilion zones from eight markets, showcasing innovation
trends from Mainland China, India, Indonesia, Malaysia, South Korea, Taiwan, Thailand,
Vietnam, and Egypt. The event will also provide business matching opportunities 
and over 60 academic conference sessions. Organisers expect more than 10,000 visitors
from over 70 countries during the three-day event, creating new business opportunities
throughout the exhibition.

[⌊CPHI South East Asia 2026 hosts an official press conference in Bangkok, announcing
the return of Southeast Asia's premier pharmaceutical exhibition to Queen Sirikit
National Convention Center, 8–10 July 2026. The event will bring together over 400
exhibitors and 10,000 visitors from 70+ countries under the theme "The Gateway to
the ASEAN Pharma Industry."⌉⌊CPHI South East Asia 2026 hosts an official press conference
in Bangkok, announcing the return of Southeast Asia's premier pharmaceutical exhibition
to Queen Sirikit National Convention Center, 8–10 July 2026. The event will bring
together over 400 exhibitors and 10,000 visitors from 70+ countries under the theme"
The Gateway to the ASEAN Pharma Industry."⌉[
CPHI South East Asia 2026 hosts an 
official press conference in Bangkok, announcing the return of Southeast Asia’s 
premier pharmaceutical exhibition to Queen Sirikit National Convention Center, 8–
10 July 2026. The event will bring together over 400 exhibitors and 10,000 visitors
from 70+ countries under the theme "The Gateway to the ASEAN Pharma Industry."

**Ms. Rungphech Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets**
said, "The pharmaceutical industry in Thailand continues to show strong growth potential,
supported by several factors including the country’s transition into a fully aged
society, the increasing prevalence of non-communicable diseases (NCDs), healthcare
system expansion, growth in medical tourism, and the use of essential medicines 
in hospitals under Thailand’s universal healthcare system.

In 2024, Thailand’s pharmaceutical industry was valued at approximately THB 240 
billion (around 6.9 billion dollars), and is projected to grow by 6–7% due to these
supporting factors. Market research agencies also forecast that by 2030, the industry
could reach a value of 480 billion baht or 13.9 billion dollars.

[⌊Industry and government leaders take part in a panel discussion at the CPHI South
East Asia 2026 press conference, highlighting Thailand's role as the region's pharmaceutical
manufacturing hub.⌉⌊Industry and government leaders take part in a panel discussion
at the CPHI South East Asia 2026 press conference, highlighting Thailand's role 
as the region's pharmaceutical manufacturing hub.⌉[
Industry and government leaders
take part in a panel discussion at the CPHI South East Asia 2026 press conference,
highlighting Thailand’s role as the region’s pharmaceutical manufacturing hub.

Another key trend to watch is the increasing push from both the public and private
sectors toward pharmaceutical development and innovation, including both generic
drugs and newly developed medicines. This aligns with government efforts to strengthen
pharmaceutical security.

Pharmaceutical and healthcare security has therefore become a national policy priority
aimed at raising public healthcare standards and strengthening the country’s economy
as Thailand seeks to join the OECD within five years. Policies also focus on reducing
reliance on imported medicines, supporting domestic active pharmaceutical ingredient(
API) production, and increasing manufacturing capacity for essential medicines in
line with actual production costs.

This is the driving force behind the organization of CPHI South East Asia, a technology
and innovation exhibition with the important goal of contributing to Thailand’s 
pharmaceutical security. The event aims to help drive both healthcare and the economy
forward, positioning Thailand as a Medical Hub for Southeast Asia through internationally
standardized pharmaceutical manufacturing and enhanced competitiveness in global
export markets.

[⌊Food and Drug Administration Office (Thai FDA), Thai Pharmaceutical Manufacturers
Association (TPMA), Government Pharmaceutical Organization (GPO),industry leaders
gather at the CPHI South East Asia 2026 press conference in Bangkok, united in advancing
Thailand's position as Southeast Asia's leading Medical Hub.⌉⌊Food and Drug Administration
Office (Thai FDA), Thai Pharmaceutical Manufacturers Association (TPMA), Government
Pharmaceutical Organization (GPO),industry leaders gather at the CPHI South East
Asia 2026 press conference in Bangkok, united in advancing Thailand's position as
Southeast Asia's leading Medical Hub.⌉[
Food and Drug Administration Office (Thai
FDA), Thai Pharmaceutical Manufacturers Association (TPMA), Government Pharmaceutical
Organization (GPO),industry leaders gather at the CPHI South East Asia 2026 press
conference in Bangkok, united in advancing Thailand’s position as Southeast Asia’s
leading Medical Hub.

**Ms. Rungphech added**, "Pharmaceutical security is a shared responsibility and
a foundation of human security. Government and private sector must work in tandem
to ensure Thailand not only has access to medicines, but becomes a country that 
the world trusts to produce them."

"CPHI South East Asia is part of International Healthcare Week and will be held 
at Queen Sirikit National Convention Center from 8–10 July 2026 under the theme _"
The Gateway to the ASEAN Pharma Industry."_ The event will contribute to advancing
Thailand’s pharmaceutical industry in line with the country’s strategic development
goals."

**Ms. Supatra Boonserm, Secretary-General of the Food and Drug Administration (FDA),**
under the Food and Drug Administration Office (Thai FDA), Ministry of Public Health,
stated that in a world where medical technology continues to advance rapidly, we
are now entering the era of Advanced Therapy Medicinal Products (ATMPs). These are
no longer just "medicines" in the traditional sense, but represent "new hope" for
treating diseases once considered incurable — whether through cell therapy, gene
therapy, or tissue engineering.

Today, the role of the Thai FDA is no longer limited to being merely a "regulator"
responsible for screening product safety. It has evolved into an "Innovation Facilitator,"
aiming to position Thailand as a true regional healthcare hub. The FDA’s key mission
in supporting ATMPs is built upon three major pillars:

**1.Creating a Regulatory "Fast Track" (Regulatory Excellence)**

Complex innovations require regulations that are both flexible and rigorous. The
FDA has therefore developed legal frameworks aligned with international standards,
covering product classification and dedicated GMP standards specifically for ATMPs.
This ensures that products developed by Thai innovators meet global standards and
can confidently compete in international markets.

**2. Serving as a Strategic Partner for Researchers and Entrepreneurs (Proactive
Partnership)**

The FDA has implemented a Pre-submission Consultation mechanism to provide technical
guidance before formal approval applications are submitted. It has also introduced
Fast Track pathways for products addressing urgent medical needs, helping reduce
unnecessary delays and barriers while maintaining patient safety as the highest 
priority.

**3. Building an "Ecosystem of Trust" (Ecosystem of Trust)**

The FDA oversees clinical trials to ensure ethical compliance and maintains long-
term post-market safety monitoring systems. This is intended to build confidence
among both patients and healthcare professionals that these innovations will remain
effective and safe in a sustainable manner.

**Mr. Surachai Ruengsuksilp, Honorary Chairman of the Pharmaceutical Industry Group
under the Federation of Thai Industries and Vice President of the Thai Pharmaceutical
Manufacturers Association (TPMA)**, stated that the pharmaceutical industry is not
merely an economic driver, but also a "critical infrastructure for national security."

Currently, Thailand’s pharmaceutical market is valued at more than THB 240 billion.
Amid these opportunities, the Federation of Thai Industries has established a strategic
direction to position Thailand as a full-fledged Regional Pharma Hub through three
key strategies:

**1.Transforming from an "Importer" to a "Producer for Security"**

Reducing dependence on imported medicines by promoting domestic production of Active
Pharmaceutical Ingredients (APIs), thereby reducing vulnerability to global crises.

**2. Upgrading from "Basic Medicines" to "Advanced Innovation"**

Supporting Thai pharmaceutical manufacturers in upgrading to internationally recognized
PIC/S GMP standards, enabling Thai medicines not only to serve the CLMV market but
also to expand exports globally.

**3. Building a Strong Pharmaceutical Ecosystem**

Driving collaboration with the government and the Board of Investment (BOI) to create
an investment environment conducive to research and development, while also reforming
procurement regulations to better reflect actual quality-based costs. This is intended
to help Thai pharmaceutical companies remain competitive and achieve sustainable
growth.

The Federation of Thai Industries aims to make Thailand "a regional production base
for high-quality and affordable medicines," focusing not only on economic growth
figures, but also on ensuring that Thai people have sufficient access to safe medicines
under all circumstances.

**Dr.Ponthip Wirachwong Ph.D. Deputy Managing Director, Government Pharmaceutical
Organization (GPO),** stated that beyond its primary role in pharmaceutical manufacturing,
the organization’s core mission is to ensure confidence in Thailand’s healthcare
system by guaranteeing that Thai people will never face medicine shortages during
crises or at any time.

In the past, Thailand has experienced epidemics and natural disasters, and the GPO
has maintained reserve systems for essential medicines and medical supplies to ensure
that hospital operations can continue without disruption caused by delays.

"Even the most advanced medicine fails if it remains out of reach. GPO’s mission
is simple: ensure every Thai patient has access to safe, quality medicines — at 
a price that doesn’t force them to choose between health and survival," she said.

**Pre-registration is now open for visitors and exhibitors. Be part of the future
of ASEAN’s pharma industry at **[**www.cphi.com/sea**](http://www.cphi.com/sea)

**For media enquiries, please contact:**
Gautam JatwaniSenior Marketing Manager[Gautam.jatwani@informa.com](https://www.thailand-business-news.com/pr-news/Gautam.jatwani@informa.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia ](http://www.prnasia.com/story/archive/4966198_AE66198_0?rand=184833)